| 001 | 168307 | ||
| 005 | 20240229133604.0 | ||
| 024 | 7 | _ | |a 10.21873/anticanres.14957 |2 doi |
| 024 | 7 | _ | |a pmid:33813396 |2 pmid |
| 024 | 7 | _ | |a 0250-7005 |2 ISSN |
| 024 | 7 | _ | |a 1791-7530 |2 ISSN |
| 024 | 7 | _ | |a altmetric:106751683 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-00818 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Zwicker, Felix |0 P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Hypofractionated Radiotherapy With Simultaneous-integrated Boost After Breast-conserving Surgery Compared to Standard Boost-applications Using Helical Tomotherapy With TomoEdge. |
| 260 | _ | _ | |a Attiki |c 2021 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1618987721_5527 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:E055# |
| 520 | _ | _ | |a This comparative plan study examines a range of boost-radiation methods in adjuvant radiotherapy of breast cancer using helical intensity-modulated radiotherapy with TomoEdge-technique. Impact of hypofractionated radiation with simultaneous-integrated boost (SIB) and influence of differing assumed α/β-values were examined.For 10 patients with left-sided breast cancer each four helical IMRT-plans with TomoEdge-technique were created: hypofractionated+SIB (H-SIB) (42.4/54.4 Gy, 16 fractions), normofractionated+SIB (N-SIB) (50.4/64.4 Gy, 28 fractions), hypofractionated+sequential-boost (H-SB) (42.4 Gy/16 fractions+16 Gy/8 fractions), normofractionated+ sequential-boost (N-SB) (50.4 Gy/28 fractions+16 Gy/8 fractions). Equivalent doses (EQD2) to organs-at-risk (OAR) and irradiated mammary-gland were analysed for different assumed α/β-values.The mean EQD2 to OAR was significantly lower using hypofractionated radiation-techniques. H-SIB and H-SB were not significantly different. H-SIB and N-SIB conformed significantly better to the breast planning-target volume (PTV) and boost-volume (BV) than H-SB and N-SB. Regarding BV, mean EQD2 was significantly higher for all α/β-values investigated when using H-SIB and N-SIB. Regarding PTV, there were no clinically relevant differences.Relating to dosimetry, H-SIB is effective compared to standard-boost-techniques. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |x 0 |f POF IV |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a Hypofractionated radiotherapy |2 Other |
| 650 | _ | 7 | |a IMRT |2 Other |
| 650 | _ | 7 | |a SIB |2 Other |
| 650 | _ | 7 | |a TomoEdge |2 Other |
| 650 | _ | 7 | |a breast cancer |2 Other |
| 650 | _ | 7 | |a helical tomotherapy |2 Other |
| 650 | _ | 7 | |a simultaneous integrated boost |2 Other |
| 700 | 1 | _ | |a Hoefel, Sebastian |b 1 |
| 700 | 1 | _ | |a Kirchner, Corinna |b 2 |
| 700 | 1 | _ | |a Huber, Peter E |0 P:(DE-He78)3291aaac20f3d603d96744c1f0890028 |b 3 |u dkfz |
| 700 | 1 | _ | |a Debus, Juergen |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Schempp, Michael |b 5 |
| 773 | _ | _ | |a 10.21873/anticanres.14957 |g Vol. 41, no. 4, p. 1909 - 1920 |0 PERI:(DE-600)2145376-7 |n 4 |p 1909 - 1920 |t Anticancer research |v 41 |y 2021 |x 1791-7530 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:168307 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)3291aaac20f3d603d96744c1f0890028 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Imaging and radiooncology |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-31 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-31 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ANTICANCER RES : 2019 |d 2021-01-31 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-01-31 |
| 920 | 1 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Translationale Radioonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E055-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E050-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::